An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects
Latest Information Update: 13 Jun 2025
At a glance
- Drugs DA-5222 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Dong-A ST
Most Recent Events
- 13 Jun 2025 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 06 Jun 2025 Planned initiation date changed from 22 May 2025 to 1 Jun 2025.
- 04 Jun 2025 New trial record